Asleh R - Search Results

1

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction.

Schwartz A, Blum S, Asleh R, Pollak M, Kalet-Litman S, Levy AP. Schwartz A, et al. Among authors: asleh r. Pharmgenomics Pers Med. 2009;2:1-8. doi: 10.2147/pgpm.s4608. Epub 2009 Feb 27. Pharmgenomics Pers Med. 2009. PMID: 23226030 Free PMC article.

2

Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice.

Khalil F, Asleh R, Perue RK, Weinstein JM, Solomon A, Betesh-Abay B, Briasoulis A, Alnsasra H. Khalil F, et al. Among authors: asleh r. Biomedicines. 2023 Mar 2;11(3):757. doi: 10.3390/biomedicines11030757. Biomedicines. 2023. PMID: 36979735 Free PMC article. Review.

3

Cardiac Transplantation: Physiology and Natural History of the Transplanted Heart.

Asleh R, Alnsasra H, Villavicencio MA, Daly RC, Kushwaha SS. Asleh R, et al. Compr Physiol. 2023 Jun 26;13(3):4719-4765. doi: 10.1002/cphy.c220001. Compr Physiol. 2023. PMID: 37358515

4

Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients.

Dagan M, Kolben Y, Goldstein N, Ben Ishay A, Fons M, Merin R, Eisenkraft A, Amir O, Asleh R, Ben-Yehuda A, Nachman D. Dagan M, et al. Among authors: asleh r. J Clin Med. 2022 Dec 21;12(1):45. doi: 10.3390/jcm12010045. J Clin Med. 2022. PMID: 36614848 Free PMC article.

5

Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease.

Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Asleh R, et al. Circ Res. 2003 Jun 13;92(11):1193-200. doi: 10.1161/01.RES.0000076889.23082.F1. Epub 2003 May 15. Circ Res. 2003. PMID: 12750308

6

Tyrosine kinases inhibitors block Fas-mediated deleterious effects in normoxic and hypoxic ventricular myocytes.

Shilkrut M, Yaniv G, Asleh R, Levy AP, Larisch S, Binah O. Shilkrut M, et al. Among authors: asleh r. J Mol Cell Cardiol. 2003 Oct;35(10):1229-40. doi: 10.1016/s0022-2828(03)00232-3. J Mol Cell Cardiol. 2003. PMID: 14519433

7

Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes.

Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A, Miller-Lotan R, Hammerman H, Levy AP. Sulieman M, et al. Among authors: asleh r. Diabetes Care. 2004 Nov;27(11):2730-2. doi: 10.2337/diacare.27.11.2730. Diabetes Care. 2004. PMID: 15505013 No abstract available.

8

Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo.

Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Asleh R, et al. Circ Res. 2005 Mar 4;96(4):435-41. doi: 10.1161/01.RES.0000156653.05853.b9. Epub 2005 Jan 20. Circ Res. 2005. PMID: 15662028

9

Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Suleiman M, et al. Among authors: asleh r. Diabetes. 2005 Sep;54(9):2802-6. doi: 10.2337/diabetes.54.9.2802. Diabetes. 2005. PMID: 16123372

10

Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo.

Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP. Asleh R, et al. Circ Res. 2006 Dec 8;99(12):1419-25. doi: 10.1161/01.RES.0000251741.65179.56. Epub 2006 Nov 2. Circ Res. 2006. PMID: 17082477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters